M
Michael Mayne
Researcher at National Research Council
Publications - 31
Citations - 2271
Michael Mayne is an academic researcher from National Research Council. The author has contributed to research in topics: Ryanodine receptor & Tumor necrosis factor alpha. The author has an hindex of 22, co-authored 31 publications receiving 2201 citations. Previous affiliations of Michael Mayne include University of Manitoba & University of Prince Edward Island.
Papers
More filters
Journal ArticleDOI
Presenilin-1 Mutations Increase Levels of Ryanodine Receptors and Calcium Release in PC12 Cells and Cortical Neurons
Sic L. Chan,Michael Mayne,Clark P. Holden,Jonathan D. Geiger,Mark P. Mattson,Mark P. Mattson +5 more
TL;DR: It is reported that PC12 cells expressing PS1 mutations and primary hippocampal neurons from PS1 mutant knockin mice exhibit greatly increased levels of ryanodine receptors (RyR) and enhanced Ca2+ release following stimulation with caffeine.
Journal ArticleDOI
The Tat Protein of HIV-1 Induces Tumor Necrosis Factor-α Production IMPLICATIONS FOR HIV-1-ASSOCIATED NEUROLOGICAL DISEASES
TL;DR: It is suggested that Tat may provide an important link between HIV and macrophage/glial cell activation and suggest new therapeutic approaches for HIV dementia.
Journal ArticleDOI
Neuronal death induced by brain-derived human immunodeficiency virus type 1 envelope genes differs between demented and nondemented AIDS patients.
Christopher Power,Justin C. McArthur,Avindra Nath,Kathy Wehrly,Michael Mayne,J. Nishio,T. Langelier,Richard T. Johnson,Bruce Chesebro +8 more
TL;DR: The HIV-1 envelope diversity observed in these patient groups appeared to influence the release of neurotoxic molecules from macrophages and might account in part for the variability in occurrence of dementia in AIDS patients.
Journal ArticleDOI
The case for strategic international alliances to harness nutritional genomics for public and personal health
Jim Kaput,Jose M. Ordovas,Lynnette R. Ferguson,Ben van Ommen,Raymond L. Rodriguez,Lindsay H. Allen,Bruce N. Ames,Kevin Dawson,Bruce German,Ronald M. Krauss,Wasyl Malyj,Michael C. Archer,Stephen Barnes,Amelia Bartholomew,Ruth Birk,Peter J. van Bladeren,Kent J. Bradford,Kenneth H. Brown,Rosane Caetano,David Castle,Ruth Chadwick,Stephen L. Clarke,Karine Clément,Craig A. Cooney,Dolores Corella,Ivana Beatrice Manica da Cruz,Hannelore Daniel,Troy Duster,Sven O. E. Ebbesson,Ruan M. Elliott,Susan J. Fairweather-Tait,Jim Felton,Michael Fenech,John W. Finley,Nancy Fogg-Johnson,Rosalynn Gill-Garrison,Michael J. Gibney,Gillies Peter John,Jan-Åke Gustafsson,John L. Hartman,Lin He,Jae-Kwan Hwang,Jean-Philippe Jais,Yangsoo Jang,Hans Joost,Claudine Junien,Mitchell M. Kanter,Warren A. Kibbe,Berthold Koletzko,Bruce R. Korf,Kenneth S. Kornman,David W. Krempin,Dominique Langin,Denis R. Lauren,Jong Ho Lee,Gilbert A. Leveille,Su-Ju Lin,John C. Mathers,Michael Mayne,Warren C. McNabb,John A. Milner,Peter Morgan,Michael Müller,Yuri Nikolsky,Frans van der Ouderaa,Taesun Park,Norma Ana Pensel,Francisco Pérez-Jiménez,Kaisa Poutanen,Matthew A. Roberts,Wim H. M. Saris,Gertrud U. Schuster,Andrew N. Shelling,Artemis P. Simopoulos,Sue Southon,E. Shyong Tai,Bradford Towne,Paul Trayhurn,Ricardo Uauy,Willard J. Visek,Craig H Warden,Rick Weiss,John K. Wiencke,Jack Winkler,George L. Wolff,Xi Zhao-Wilson,Jean-Daniel Zucker +86 more
TL;DR: In this paper, the authors provide specific recommendations for how to best meet this challenge and discuss the need for new methodologies and the use of comprehensive analyses of nutrient-genotype interactions involving large and diverse populations.
Journal ArticleDOI
Antisense Oligodeoxynucleotide Inhibition of Tumor Necrosis Factor-α Expression Is Neuroprotective After Intracerebral Hemorrhage
Michael Mayne,W. Ni,Hui-Jin Yan,Mengzhou Xue,J. B. Johnston,M. R. Del Bigio,James Peeling,Christopher Power +7 more
TL;DR: It is demonstrated that reducing TNF-&agr; expression using antisense oligodeoxynucleotides is neuroprotective and indicates a pathogenic role for TNF; during ICH and shows improvement in neurobehavioral deficits at 28 days after hemorrhage induction.